Table 3.

Consensus meeting results

	Inclusion	Exclusion	Pre-op biopsy strategy	Biopsy end point	PSA	MRI	Treatment failure	Re-treatment
Van den Bos et al. [61] Multi-stage Delphi process	3 + 3 with “substantial cancer” 3 + 4 >10-year life expectancy PSA > 15 with caution	Clinically insignificant disease (volume < 0.5 cc)	MRI targeted or fusion with systematic	Negative 12-month biopsies Targeted and systematic	3 monthly but not sufficient as an end point	Alterations in MRI not sufficient as end point	Any cancer in-field of treatment Low-grade, low-volume (Gleason 6, <3 mm) out of field is not considered failure	Acceptable on one occasion
Donaldson et al. [59] RAND/UCLA appropriateness methodology	NCCN intermediate risk disease 3 + 3 with >3–5 mm MCCL >10-year life expectancy Multifocal disease included (secondary lesion of Gleason 6, ≤5 mm can be left untreated)	<5-year life expectancy and those <40 and >80 years with caution WHO performance status 3–4	MRI targeted or template mapping (if no MRI available)	12-month biopsy Targeted only Uncertainty about systematic sampling	Rising PSA may trigger biopsy	Suspicious MRI may trigger biopsy	Cancer in field of equivalent or higher than pre-operative grade Low-grade, low-volume (Gleason 6, <3 mm) in field is not considered failure	≤20 % retreatment rates
Muller et al. [60] Delphi process				12 month biopsy Targeted and systematic	3 monthly No consensus on role of PSA	1st MRI 6 months post-treatment Suspicious MRI should lead to biopsy Further biopsies after 12 months only if suspicious MRI